🔵 Sign up for the American Thought Leaders ALERTS newsletter to stay up-to-date on new episodes, releases, and special events 👉 https://ept.ms/ATLnewsletter
“We get a lot of inappropriate over-prescribing for almost everything,” argues drug policy researcher and journalist Alan Cassels.
Cassels is the co-author of “Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients.”
For Cassels, it was one disease in particular—osteoporosis—that changed his entire view of medicine. Based on changing definitions of the disease, large swaths of Americans could suddenly be declared sick and in urgent need of drug treatment.
They “medicalized normal aging of the basically entire female population. Overnight,” he argues.
In our interview we discuss the influence of the pharmaceutical industry over diagnoses and prescriptions and how the criteria for many diseases can be expanded arbitrarily.
“When you look closely at the quality of prescribing, a lot of times, the decision making is not really driven by evidence. It's driven mostly by … marketing, biases, influence from thought leaders and influence from guidelines, medical guidelines themselves, which are often appallingly biased,” he says.
Many doctors, Cassels says, know little about adverse effects of the many drugs they prescribe their patients.
We also dive into the connection between psychiatric drug prescriptions and violence, how psychiatry labels normal behaviors as abnormal, and how exaggerated statistics are used to sell theories of disease and drug treatments.
Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.
We know that the rate of effect effects
are much greater than 1%.
>> Right?
So you're promoting this drug on the
basis of a misleading reduction. We
still see this today. In this episode, I
sit down with Alan Castles, a health
policy researcher and author of selling
sickness. He highlights the risk and
adverse effects of antiscychotics and
anti-depressants, including violent
behavior. And often times when these
violent attacks happen, nobody is
sitting down and asking what kind of
drugs was the person taking and what
kind of, you know, prescribing were
they, you know, experiencing. How are
medical conditions exaggerated to drive
increased drug prescriptions?
>> What used to be considered to be
autistic behavior. There might be, say,
15 to 20 different symptoms. If the
child exhibits 10 of them, they might be
considered to have autism. Now they only
have to exhibit six of them. Castles
warns against fear-based marketing and
encourages careful consideration of
prescriptions, especially for chronic
conditions. Stop allowing yourself to be
made afraid by those who are selling
treatments. If you're facing the sharp
end of a prescription pad, you have time
to think about it. This is American
Thought Leaders and I'm Yell
Alan Castles. Such a pleasure to have
you on American Thought Leaders.
>> It's great to be here.
>> So what's the answer to the question,
are we looking in the right place for
answers to violent attacks? So when you
think about violent attacks, you think
of people who have psychiatric problems,
for example, and often times when they
investigate that, they look at the kind
of psychiatric care a person might be
under. What they're not questioning
though is the is the is the quality of
the prescribing that goes into a lot of
psychiatric care. And in fact we know
that one of the main adverse effects
related to psychiatric drugs I'm
speaking broadly here but specifically
say antiscychotics or anti-depressants
is violent behavior uh suicide homicide
these are all known dangers to these
drugs and often times when these violent
attacks happen such as we had in in uh
in Canada where um a a person drove a a
vehicle into a a group of people having
a street festival
when they examine this they nobody is
sitting down and asking what kind of
drugs was the person taking and what
kind of you know prescribing were they
you know experiencing and I think that's
probably the first place you should look
and often times it gets overlooked
altogether because people will assume
that if whatever psychiatric care
they're under it must be sort of
guideline care and and approved but
really we have to stop back step back
and say look um we're probably causing a
lot of the uh psychiatric um outbursts
by the kinds of prescribing that we do.
>> Now, is this because of rare effects
that maybe even some of the doctors
might not be aware of or is it what is
the reason for?
>> Well, doctors lack of cognition around
adverse effects related to drugs is well
known. I mean, this has been been well
studied. Physicians don't learn about
the adverse effects of drugs largely
because they're not exposed to that
through a lot of the marketing that they
get. And of course, a lot of the
information that physicians get around
drugs comes from the hands of the
pharmaceutical companies and not they're
not exactly promoting the adverse
effects of their drugs. Is there some
way to quantify how big a problem this
is? Like how often the drugs might have
been responsible or partially
responsible in situations where that
hasn't been looked at.
>> Yeah, it's a good question. I don't
think it's been it's been adequately
studied, but I think if you talk to the
experts that are um you know well-versed
in sort of the adverse effects of
psychiatric drugs, they would say most
of the time you can you can you can draw
conclusions by um by looking at the the
drugs that persons being prescribed.
>> Uh but so maybe dig into that a little
because what you're describing is not
something that's obvious. Yeah, it's not
obvious, but I mean, let's put it this
way. We we assume as consumers, as
patients, that when uh we're presented
to a physician with a particular disease
that that the um the decision making
around your condition and how to treat
it in terms of some kind of therapy or
drug that you might get is
evidence-based. It's based on a
physician's careful, you know,
assessment of the science and assessment
of your disease. Though, when you look
closely at at at the the quality of
prescribing, a lot of times the that
decision-m is not really driven by
evidence. It's driven mostly by
sometimes marketing, by biases, uh uh
influence from thought leaders and
influence from guidelines, medical
guidelines themselves, which are often
uh appallingly biased. I'll give you an
example. So someone who uh who presents
with high blood sugar, you know, might
be a precursor to pre-diabetes or
diabetes. Um physician will assume that
because the guidelines and this is the
level at which that you should start
taking some kind of treatment to to
alter your blood sugars without knowing
that people who wrote the guidelines
are heavily funded by the pharmaceutical
companies. And in fact, the Canadian
guidelines, the conflicts of interest of
of the uh of the authors of the
guidelines fills up 15 or 20 pages. So,
um what's clear to us who independently
look at this kind of thing is that the
pharmaceutical companies are very good
at putting their own people on guideline
committees and that's why we get we end
up in a situation where we get a lot of
inappropriate and overprescribing for
almost everything. Now with that
particular scenario, I recall some
instance and maybe it was a different
drug, but where the the level of blood
sugar was moved to something lower,
right? You would not believe how often
they move the the goalposts. Give you an
example. The probably the best example
is not blood sugar, it's blood pressure.
Okay? So 20 years ago, if you came in
and your doctor said your blood pressure
is 150 over 90, they would say it's a
little on the high side. no problem. You
know, maybe you should exercise some
more, reduce the salt in your diet.
Today, now that over time, that 150 over
90 has been lowered to 140 to 130 and
now it's around 120. Well, when you
lower the level at which you start
treating someone or telling someone that
they're ill or potentially ill from high
blood, you expand the massive pool of
people that become patients. And this is
one of the the the key things behind
disease mongering. When you change the
definitions of what the disease is, you
expand the pool. They never change the
def definitions that that reduce the
size of the pool because again the
pharmaceutical companies are very very
involved in the writing of the
guidelines. But we document that in in
celling sickness how by just by lowering
say the level at which we would consider
high cholesterol to be a condition uh
overnight they would expand um the
number of Americans who would be treated
for cholesterol-lowering drugs by 25
million people just by changing the
definition.
>> So I mean you're describing I think a
very powerful incentive structure uh to
um do precisely that.
>> Exactly. I mean the the incentives are
all in the direction of the
pharmaceutical companies and for uh
those who who are funded by the
pharmaceutical companies including the
patient groups and specialty societies
and so on. Absolutely. Um but what's
what's kind of missing from this uh
situation is that you don't have enough
people perhaps like me who are
critiquing this and saying just hang on
a second you just move the goalpost.
you're not actually expanding the number
of people who are going to be uh um
considered well. You're you're expanding
the group of people who are considered
sick. So you're actually creating
illness. You're creating a sense of ill
ease amongst the population. When you
start telling people um your blood
pressure needs to be at this level,
otherwise you're unhealthy. And this
idea that telling people that they're
not healthy when they otherwise are is
really the the essence of disease
mongering. This is something that I've
written quite a bit about.
>> This is your your term. I think you
coined the term disease mongering.
>> I wrote the book.
>> Yes.
So I I wrote a a a funny little book
called the ABCs of disease mongering
because I wanted to describe in 26
letters how we see this kind of um
creation and marketing of illness from
cradle to grave from from from babies to
people who are at the end of their lives
where normal just human changes in
physiology and your life as you as you
age becomes another reason for which
another drug might be prescribed. So,
you know, yeah, you're right. There's
there's definitely a a a campaign, shall
we say, to get more and more of us to
become uh to to to be ill. So, one thing
comes to mind in the US, there's been a
lot of discussion about autism rates
growing, you know, in a way that's
frankly shocking when you look at these
graphs. Now, what what's very curious
about this is that I think it's actually
kind of industry that's saying this is a
function of precisely what we've just
been describing of the goalpost being
moved. So, now we're just overdiagnosing
autism a lot more.
>> Well, absolutely. We we we have it used
to be for example and I've
>> but that's what that's but this is a
curious situation because I think it's
the industry that's saying that whereas
it's the people who are like yourself
like activists are saying the opposite.
No, that this is actually this is
actually a real shift. Well, on on this
point around autism, same with the
attention deficit disorder. I would
agree with that where they have changed
the goalpost on what used to be
considered to be autistic behavior or
say on the spectrum 15 or 20 years ago,
there might be say 15 to 20 different
symptoms if and and of this checklist of
symptoms, if the child exhibits 10 of
them, for example, they might be
considered to have autis autism. Well,
they've changed that over time. So now
they only have to exhibit six of them or
four of them. And so when you again when
you do that, you're expanding the pool
of people who begin to take this label
and perhaps to be accepted for treatment
for it. And as you know, there's a whole
industry around autism. At the same
time, you have to ask yourself, is there
actual things in medicine or in society
that might be causing neurodedevelopment
problems in children? And that's when
you start looking at things like drugs
or perhaps vaccines, right? Just putting
that out there that those things need to
be adequately studied in order to be
able to determine what is actually
causing this apparent rise in autism or
ADHD.
So, but basically you're saying that
both things can be very much true that
there is a there could be a rise in
these neurodedevelopmental
um issues but and at the same time
autism itself could be overdiagnosed
because it serves the interest of people
who want to provide drugs around that.
>> Absolutely. And you know you hear
anecdotes of parents who want a
diagnosis for their child because that's
going to get them special care or extra
extra help in school and so on. You
certainly see that in the area of of
ADHD where it actually comes as a relief
to some parents that oh my goodness, my
son now has ADHD and therefore is is
eligible for some extra extra help or uh
in in school.
Hey, if you enjoyed this clip, I've
interviewed over a thousand thought
leaders, people who are mavericks in
their fields. These interviews all live
here in the link below. We have an
incredible deal going on today. Check it
out.
>> Explain to me um you kind of describe
this almost like a you know a system.
It's this disease mongering is a
systemic thing.
>> It's something that's almost done in in
every area. Give me some examples where
where we see that.
>> Well again it's a cradle to grave
phenomena. I maybe start from the closer
to the end of people's lives. And this
is something that I became aware of 30
years ago. And when I started becoming
aware of this one disease and to see to
which the industry had infiltrated
itself into the definition of the
disease, it cha changed my whole view of
medicine and that was osteoporosis.
And you know in the early '9s uh a major
pharmaceutical company in the US created
a new drug to treat this condition
osteoporosis which at that point wasn't
very well understood. In fact there
wasn't really an agreed upon definition.
Uh there was a a meeting convened at the
World Health Organization and at that
meeting there were you know officials
there were endocrinologists and others
and representatives from pharmaceutical
companies that were making drugs that
were going to treat this condition. And
there they set the definition at a
certain level of bone density. So this
is the the density of your bones as you
age. They set it at a certain level in a
way that you would have diagnosed
something like 50% of the female
population over 70 with having this
condition. They set the definition that
way and basically said overnight that
this uh this portion of the population
that has bone density below this now has
this condition called osteoporosis or if
it's close to that they might have
something that is pre-ostoporosis or
known as osteopenia.
And what you ended up doing is you
medicalize normal aging of the basically
entire female population overnight. That
drug became a blockbuster drug. uh
prescribed, you know, widely. The
company that was marketing it bought
bone density testing equipment and
distributed through all the clinics and
and and hospitals throughout the US and
basically overnight created a condition
that is a normal part of aging.
um and and really just basically
medicalized one's bones that has gone on
to be extremely controversial because
that drug you know after time when you
get millions of people taking a drug
that's when you start seeing the major
problems severe problems with swallowing
and esophageal burning and and and and
really over the long term and this is
cruel and ironic at the same time th
those drugs they're called the
bisphosphinates drugs in those in that
class of um uh drugs found that um over
time it actually makes people's bones
more brittle. So more prone to being to
to breaking. I mean admittedly elderly
people falling breaking a hip can be a
quite serious problem. Often times that
can lead to you know disability nursing
homes and sort of the beginning of the
end of a person's life. Absolutely you
want to do what you can to reduce the
sort of um problems of broken bones and
elderly people but preventing falls
should be the should be the focus. Not
using a drug that's going to alter alter
the chemical composition of your bones
which ends up becoming uh uh something
that made your bones more brittle. Again
that was a that was from start to finish
I would say a pharmaceutical industry
construct. And now they've gone on,
they've moved on to other classes of
drugs. But still, I have friends of mine
who would be my age in their 50s and
60s. They're on a on a bicycle, they
fall off, they break their wrist or
they're skiing or in an accident, they
get sent to their doctor. The first
thing they do, they'll send them for a
bone density test and they'll say, "Oh,
you have pre-ostrioporosis."
It drives me crazy because they are they
are using the the broken bone as a
pretext for explaining to a person that
they now have this disease and they
possibly could be a candidate for a
drug. I mean this is this is forgive me
I'm going to play advocate to the devil
here a little bit but you know some
people have low bone density and
probably need some kind of help but it's
it's never the drug that will be helpful
for this in your view.
>> Well it depends. So what so what is the
problem that we're trying to solve here?
There is a whole range of different bone
densities. A lot of people live
perfectly well and and and and quite
healthily with low bone density. It's
not it's not something that it's kind of
like developing gray hair and wrinkles.
Eventually your bone density will change
over time and it will become lower than
it was when you were in your 30s. I
mean, that was the other problem with
the bone density measurement is that
they were comparing women in their 70s
to women in their 30s and then they were
pointing them and said, "Well, they have
low bone density." Well, they have lower
bone density than they did when they
were young, active, and probably in the
in in the prime of their life. So, yes.
So, is there a problem with people
having low bone density? If if if people
are repeatedly falling and breaking
bones, yes, that can be a problem. But I
could be wrong, but I don't believe
there's any drug in the world that's
going to prevent someone from breaking a
bone if they fall.
>> So the idea that this drug will
somehow prevent breaks when people fall,
that is untrue.
>> It's totally untrue because I mean even
even when they Okay, I'll give you an
example of how crazy this was. They
marketed this drug and and the drug was
called Phosmax. It was called
Alendrinate. The the the trade name was
Fossamax generic Alendrinate. They
marketed as as reducing hip fractures by
50%. And I know cuz I've used the ads
that the company ran in M major medical
journals. I've used these ads in
presentations that I've done on this
very topic and they show a person an
elderly woman bent over and it's 50%
reduction in hip fractures. My question
is when somebody gives you a number like
that, well, how many hip fractures were
there in the placebo group mean the
women in the group and there were more
than 3,000 women in this trial that had
low bone density. They were defined as
having osteoporosis. They had had
previous fractures. They have low bone
density. So, they're high risk. How many
of these high-risisk women in the course
of four years would have a hip fracture?
Well, the answer was out of two about
2%. Two out of a 100. Well, how many had
a hip fracture if they took the drug?
Well, it was one out of a 100. So, when
you go from two out of 100 down to one
out of 100, that's a 50% drug. And so,
the 50% was marketed to patients, to
doctors, to specialists. And people went
away thinking, "This drug is miraculous.
It's going to reduce our rate of hip
fracture by 50%." This is when this is
when I this is kind of what turned me
into an activist when I saw the misuse
of those numbers and how misleading that
would be for my mother or my grandmother
thinking that they're going to have a
massive effect when there's a 1%
difference.
>> Well, and it's also probably not
statistically significant at all.
>> Well, I mean, it's not it's not
clinically significant. I mean
statistics is a whole another game but
but but they they would have determined
that it was perhaps statistically
significant that you had fewer uh hip
fractures in the uh in the
bisphosphinate group but at the same
time is that meaning is that meaningful
to have a 1% difference what's how does
that compare to the rate of adverse
effects and we know that the rate of
adverse effects are much greater than
1%.
>> Right? So you're promoting this drug on
the basis of a misleading reduction. And
this happens all the time. We saw this.
We still see this today. You remember
the 95% during
>> co% rel it's the difference between
relative risk and absolute risk.
Absolutely.
>> Yeah.
>> It's just that's shocking. I mean this
is a very widely prescribed or was I I
don't know what a status is but I know
because I discussed it with my mom at
one point. Right. These are very
commonly used. Yeah. Yeah.
>> How many situations like this are there?
>> Well, in my in my book about disease m,
I have 26 examples. But yeah, this kind
of um say exact using exaggerated
statistics to sell um theories of
disease and and and and drug treatments
is um ubiquitous. It's everywhere.
Before we continue, tell me a little bit
about what you were doing when you said
you got you became an you became
radicalized, you became an activist. How
did you get into all this?
>> Oh, so so I went back to university. I
was in the I was a naval officer. I went
through military college and I was I
served in the Navy for 12 years and then
I went back to university and I started
studying a master's program in in public
administration. And I got asked at the
time if I would be interested in working
on a a project studying pharmaceutical
policy in British Columbia. And it
sounded really interesting. Yes. So I
signed up for that. And even though I
was headed for the foreign service, I
ended up becoming a drug policy
researcher and never went into the
foreign service. Um but it was it was
the one of the first studies that I was
asked to work on was developing a guide
for consumers around osteoporosis.
And that's when I started to read and
understand what a massive amount of
misleading information was out there.
And then I I took that and I said, well,
does this happen in other areas? And
then I started looking and started
working with people that were experts in
hypertension which high blood pressure.
Very similar kinds of things in terms of
the the the manipulation the in the use
of statistics in order to increase the
the um the sort of appeal of of drug
therapy, the appeal of it. Uh and and
even discovering to the degree to which
doctors are misled by the marketing
materials that they are exposed to. And
this really kind of shocked me because I
thought, you know, mo like most people,
we believe that the decisions made about
the drugs that we get every day are
mostly science-based and are based on a
good understanding of the potential
benefits and the potential harms.
>> Right?
>> And I discovered over time that is
almost that kind of um uh paradigm
doesn't exist in the real world. The
paradigm that does exist is that there
are many decisions that go into making
uh prescribing decisions and the
marketing uh of of of both the disease
and the treatment are a major part of
it. There's there's other things. I mean
we can't discount the idea of patient
demand where people are exposed to to
information from their neighbors from
advertising in
>> the US from advertising right
>> drug advertising and and start seeing
their own uh they start seeing their own
body through the lens of drug ads and
think that if they only had that drug
their life would be better you know so
so physicians respond to patient demands
we know this this has been well studied
Yeah.
>> How does this apply to psychiatric
medications?
>> Yeah. Well, so in in in in psychiatric
medicine, again, the same sort of things
apply, but what is probably the most
damaging about the I would say about the
world of psychiatry is the labeling of
of behaviors that are generally within
this uh what would used to be within the
range of normal. So you have uh boys who
are um exuberant. They've got lots of
energy. They're told to sit down, shut
up, do your work. And it's like that's
not kind of how boys learn and that's
not how boys operate. But so it's very
foreign for a lot of and I'm saying
boys, but it happens to girls as well to
be jammed into a classroom and be told
to um sit down and pay attention where
then they'd rather be running around.
boys learn kinetically through movement
and and and but but but a boy who's very
disruptive and speaks up is going to uh
make it difficult for all the other
children to learn. And therefore there
is a lot of pressure on doing something
to to prevent that uh boy's behavior
from becoming disruptive for everyone.
And that sometimes leads the road to a
diagnosis and a drug where whether it's
you know you're kind of your son has
some level of attention deficit disorder
and uh might be helped by a drug. So the
problem and there's many problems in
this par. The problem is that um we're
creating social situations and we treat
them as medical situations.
>> Right? I'll give you I'll give you
another example.
>> It could also be lack of discipline,
right?
>> Absolutely. It could be it could be the
child comes from a from a situation at
home where there's poverty, neglect,
abuse, all kinds of things which might
be affecting this child's behavior. It's
not that they have a brain disease.
They're probably reacting normally to
whatever stimuli they're getting.
>> Just to touch on this, I I don't want to
cut off your thought, but just to touch
on this a little more. I mean there's
been a the change in the educational
system where discipline isn't as valued.
>> Right. Like that isn't taught. It's like
systemically not taught at a level say
it would have been
>> some decades ago. Right.
>> Right. So that you can imagine a whole
lot more people that would benefit from
such discipline being ADHD and then
prescribed with drugs as a solution.
>> Right. Or or or people modeling
self-discipline and saying
self-discipline is actually a very good
thing. Right. Yes. Uh, totally agree.
Um, but back just one other example and
it has to do actually with ADHD. We did
a study in British Columbia now more
than 20 years ago and this was published
in the Canadian Medical Association
journal. We looked at all of the
children in British Columbia. We have a
provincewide database. You know, there's
hundreds of thousands of children in uh
in elementary school. And we looked at
the prescribing of of stimulants, drugs
for ADHD. uh and we broke it down by the
birth month. You say, "What what do you
mean by that?" Well, we broke it down
into two cohorts. The kids that were
born between January and June and the
kids that were born between July and
December. And we found that the kids
born in the latter half of the year, so
the younger kids in the class had a 40%
higher rate of ADHD drug use than the
kids born in the beginning part of the
year. We're like, "What's going on here?
there there's no difference in in brain
disease or mental disorder in younger
children versus older children. No, the
kids are less mature, possibly less able
to follow things when they're they're
that much younger because, you know, a
kid born in December is almost a year
younger than the kid born in January,
right? And they're all in the same
classroom. So, when this study came out,
I was asked by a reporter, what's going
on here? And I said point blank, we are
treating a social situation as a medical
one. And and and that's simply wrong.
You're not benefiting the the the
younger children in the classroom when
you take them and and say to them, a
certain percentage of them, you have now
a brain disease because you can't sit
still and pay attention in a classroom.
>> You just said something very powerful.
This idea, you said it twice now, but
the idea of treating a social situation
as a medical one.
>> Yeah. people identify with a certain
diagnosis that becomes part of their
identity and they um they meet others
online and this is part of who they are.
They're grasping on to explanations of
why they think a certain way or why they
act a certain way. And I think for some
people having a diagnosis brings them a
lot of comfort uh allows them to join
the tribe if you if you will. Um, but
you know, most of us will go through all
kinds of stuff when we're growing up.
You know, the ups and downs and the
normal ups and downs of of puberty and
and development and so on. But to take
those normal ups and downs, say that
that is a medical condition and then
applying whatever pharmaceutical
treatment or whatever that you can. It
seems to me completely backwards that
you know we should uh as consumers we
should push back against that because uh
we have to recognize that everyone goes
through the normal ups and downs of
development and that you will get
through it.
>> And I I I wish parents and and and young
people just had more confidence that you
you know you're going to get through
whatever it is. you're not going to have
to resort to to claiming a diagnosis,
but you're going to carry around for the
rest of your life. I mean, I think the
harm that we do in applying labels to
people is is is pretty serious and can
be longlasting. You tell a a young
rambunctious boy that he's got somehow a
mental deficit and he's going to carry
that possibly for the rest of his life.
You've damaged him. You haven't provided
any uh advance for this child. you have
damaged him by telling him he's
deficient. It's the same with uh you
know if you're telling someone, oh you
you have um you know generalized anxiety
disorder. No, you're anxious about
something that you're going to get
through. But to telling someone that
they have suddenly this medical sounding
condition is extremely damaging.
>> Well, and even in social media, I've
been observing this phenomenon. There's
almost like a valorization of certain
medical conditions like people kind of
celebrate as you said like being part of
the club or part of the group or
whatever like it becomes this identity.
What I'm thinking right now, right, is
just how bizarre it would be, right,
that we create, we basically assign a
label to someone that isn't warranted
that presumes a medical condition and
then people with that label all get
together to celebrate the fact that they
have that label.
>> I mean,
it's kind of a mess.
>> Yes, it it is an absolute mess, but it's
also very damaging. You know there was a
study and I have to tell you this
because this is something that will
affect everyone at some point in their
life. One of the most common things that
a physician will do to you when you go
for a visit is to have your blood
pressure checked, right? And you know, a
certain percentage of us are going to be
on the high side, right? What, however
it's defined. I won't give you a number
because it keeps changing. We'll say
you've got high blood pressure. They did
a study in uh in in a steel mill in
Hamilton, Ontario back in the in the in
the early 80s. And this study basically
took all of these steel workers and
measured their blood pressure. Some of
them they told the the workers that they
had high blood pressure and you know
maybe they should consider seeing their
doctor and getting treated. The others
they didn't tell them. So they had a
cohort both had some level of high blood
pressure what however it was defined at
the time. The people who were told that
they had high blood pressure. Did they
do better? So they track them and they
look them in the long term. Did they do
better in terms of job performance, life
satisfaction, happiness, things like
that? No. Actually, the people who are
given the label did worse. The people
who weren't told that they had high
blood pressure, they had to do something
about actually did better. So, this to
me is really good evidence that when you
apply a label to someone, um, you can be
causing harm. Well, and because of this,
I mean, the term is placebo effect,
right? But but point is that that and
the effect that the doctor has.
>> Yes.
>> In terms of influencing you to believe
something which is apparently huge.
>> It is. Yeah. The placebo effect, you
know, it's it's well known. We use it in
in in clinical research all the time
because we want to determine what is the
difference between the similar types of
patients. some of them who are given an
active drug and some who are given the
sort of sugar pill or inert drug because
the differences in whatever outcome
should be the differences caused by that
treatment. That's why we use the placebo
effect. You know, it's it's it's quite
interesting when you look at uh research
on anti-depressants.
You know, the people who get placeos do
very well as well. So um when they track
people over time who are who are given
placeos in in anti-depressant trials
they improve and the person on the drug
improves uh and and the person who drug
improves a little but however it's
defined by a little bit more. That's why
the drug gets gets approved but um both
patients because they're given treatment
perhaps because they're given some
attention they improve. Mhm. Except that
in many cases the placebo doesn't have
the side effects except from studies
I've seen which is I found absolutely
fascinating that if the patients know
about the potential side effect some of
them can still get the side effect on
placebo.
>> Absolutely. Absolutely. The power of
suggestion is extremely effectful right
in the sense of people are are highly
suggestible. people are easily to not
easy but many people could be easily
hypnotized because you know we're we're
we're very uh we're very suggestible.
>> There's a whole another realm to explore
with you another time. Um differences
between can the Canadian and the
American situation.
>> Yeah. Well, American medicine is is is
is as you know on steroids. Um it's a
very we we live in a very commercial
culture. uh public health for the most
part I in terms of um uh where compared
to other countries the US has a system
which is very fractured it's very
private uh and you allow certain things
in the US that you don't allow in other
countries and one example is drug
advertising so you see uh if you're
exposed to television or possibly the
internet there there are a lot of drug
ads and a lot of times these drugs are
for very rare and and and and sometimes
unheard of conditions. And the the the
powerful effect of uh of a drug ad on
consumers, it it works in two ways. One
is that there's the suggestion that a
person might be ill and could benefit
from a treatment. The pharmaceutical
industry would defend that and say, "Oh,
we're just doing disease awareness
advertising." Okay. Well, sure,
grant that might be helpful for some
people, but generally you're you you're
you're increasing the pool of people who
are exposed to disease mongering.
There's that happening. But at the same
time, when you allow that amount of of
of pharmaceutical advertising to
influence the media, you find that the
media does not really um um they they
cannot do the kind of hard-hitting
journalism that you want to see uh
because of the influence of the
advertisers. And people would say, well,
what do you mean? We've, you know, major
journals like the Wall Street Journal or
the New York Times, they get drug ads,
but also they uh have have have
>> critiques
>> critiques.
>> Yeah. I I would say that if you had no
drug advertising or no influence of the
pharmaceutical industry on the editorial
decisions of any news outlet, you would
see a whole different range of of of
reporting. Look what happened during
COVID. Virtually those who were who were
dissident or those scientists who were
questioning a lot of the public health
measures including vaccines were
censored, not allowed to give their uh
their opinions in a lot of the
mainstream medical uh or mainstream
media organizations. Um and so the
influence of the drug advertising in the
US is quite pernicious not only in
disease-mongering but also in
influencing editorial decisions around
what kind of what kind of critiques
Americans get. So I did this little
experiment with friends of mine uh a few
months ago I went to a reunion of a
bunch of old Navy buddies. Right? So
these are these are guys we're in our
60s successful businessmen. Some are
doctors, some are lawyers, businessmen
and so on. And I asked them in a small
group because they asked me, you know,
what do you do for a living? I said, do
you guys ever heard of the term vio? And
they said, well,
what's that? What's that? I said, Vio. I
said, have you ever heard of the Vietnam
War? Oh, yeah. Of course you've heard of
the Vietn Everyone's heard of the
Vietnam War. Well, did you know that
Vio, which was a a major um
pharmaceutical in the early 2000s that
was taken by um hundreds of uh thousands
of Americans, killed 60,000 Americans in
3 years from excess heart attacks and
strokes.
The Vietnam War took 12 years of
American involvement to kill about
60,000 Americans. So, Vax did uh in
three years what took the Vietkong 12
years in terms of killing Americans. And
what was so astonishing about this is
that this has been the this was probably
the most the the the biggest drug
disaster probably in our lifetime. And
these guys hadn't ever heard of it.
>> Right. And you're asking yourself, why
is that?
>> Educated.
>> How could it be?
>> Exactly. educated, well- read
um
um people
had never heard of what is considered
would be considered in my room.
>> I hadn't heard of it until the last 5
years when I yeah
>> to be the biggest drug disaster. So how
is it that we can take something that is
has been had such a profound effect on
mortality from a drug and then bury it
in a way that no one has ever heard of
it. It's amazing. It it is amazing. It
is amazing. And I think it's very
telling what you're what you're
describing because that's not a it's not
a there's no there isn't any contention
around it even. It's very it's it's
universally agreed upon to be reality.
>> Exactly. Just like the mortality the
death count in in the Vietnam War. Uh I
use this comparison. I gave a lecture in
in uh in Sweden a few months ago and I
use this comparison because Vio and V
and Vietnam both start with V. That's
what they have in common. But what do
they really have in common? They have a
death count that on one hand is highly
recognized and had a major influence on
American foreign policy. The other
is virtually unheard of by even very
educated people
>> and how much why don't you tell me how
much impact it has had on US and
Canadian drug policy. Well, I would say
that the that there was a lot of talk
about how we should tighten regulation
around uh around drug discovery and drug
marketing and and and and drug approval,
but I would argue that those those uh um
changes are not noticeable.
We have a we have a system in which uh
most people who have looked at this
would argue that the drugs that we
approved by the FDA have been uh
sometimes inadequately tested perhaps
not tested in the right population or
too short a periods of time or the
company took the data and hid part of it
or or published only the the more
favorable things. I mean, there's a
there's a million ways to bias clinical
research and but you need you need a
regulator that is strong enough to
challenge the pharmaceutical companies
and say, "Look, that's not good enough."
You know, if this drug is going to be
taken by millions of Americans, we need
good data to prove that it's going to be
safe.
>> So, there's an example just recently
with the flu vaccine about the sort of
over 65 cohort being the data set being
left out here in the US.
>> Oh, yeah. I mean that's one of of of a
of a number of problems with with
vaccine with with flu vaccine research.
I mean one of the big one of the biggest
problems that when they look at
metaanalyses so meta analysis not just
you don't cherrypick studies. If you
want to look at the flu vac you have to
look at all the studies positive and
negative. You put them together into a
systematic review and then you come out
to what we hope is the best answer of
whether the flu has benefit. When they
do that with the flu shot, they find no
benefit in in the cohorts to which it's
most marketed. And that would be elderly
people,
uh, middle-aged working people, almost
no effect of of the uh, these annual flu
campaigns. And I've I' I've studied
this. I've looked at this over the
years. You know what's a what's an
interesting comparison is when you look
at those jurisdictions that have high
coverage say a higher proportion of
their uh population getting the annual
flu shot compared to those jurisdictions
that have low coverage. We'll say you
know some states in the US you would
have more than 50 possibly 60% of the
population the working age population
getting their annual flu shot. Some
states you might have 30%. Well that's
quite a difference right? What would you
expect? Those states with the low flu
shot coverage would have a massive flu
uh influenza problem, more deaths, etc.
When they do these interstate
comparisons, there's no difference. So,
you you ask yourself, so let me get this
straight. Even though you had high
coverage in this state, you have had no
impact on the rate of flu influenza like
illness or or hospitalizations or deaths
related to flu. Right? So what you're
doing is you're you're you're you're
running a campaign that's spending a
fair bit of money
driving a certain amount of fear amongst
people thinking that if they don't get
their annual flu shot they're going to
get the flu and die and then uh you're
showing no impact with that spending of
of that money.
>> Almost unbelievable.
>> Yeah. I mean, so, so this is one of my
themes, and that is if we keep spending
money on low value care, when I say low
value care, that would be things like
flu shots for relatively healthy people,
you know, that would be um um perhaps
ADHD drugs for rambunctious children,
you know, osteoporosis drugs for people
who have normal bone density for their
age, you know, treatment of high blood
pressure for someone who has generally
normal or within a normal range of of
blood pressure. When you treat people
unnecessarily,
then you're wasting money that you could
be using on things that are actually
really important. Right.
>> Sure. And but you're also, you know, by
inference harming people that might not
need to be harmed.
>> Yeah. And you're not just harming them
um sort of medically or physically,
you're harming them fi financially. I
mean some of the biggest scandals in
medicine have to do with people who who
do have very serious diseases say uh
cancers terminal cancers and um they
prescribe drugs that we know are going
to accelerate the cancer instead of
reduce it and those drugs cost hundreds
of thousands of dollars. So you're not
only uh influencing the per having no
effect perhaps on the on the length or
the quality of a person's life but
you're also bankrupting them financially
and and and I I think that's
unconscionable that that we allow that
in this country that people say at the
end of their lives become bankrupt
because they're desperate but they're
being prescribed or treatments which
don't increase the value or the or the
quality or the length of their lives.
That's uh I mean this is a whole another
thing to unpack here. Perhaps I'll have
to I'll have to invite you back to to
discuss that. This has been an
unbelievable uh conversation. Um in some
cases literally um a final thought as we
finish. Um yeah, you know, I think a lot
about what should people do and and it's
not an easy answer to what should people
do. I don't really like to tell people
what to do, but if I could live one
piece of advice to most people is that
that stop allowing yourself to be
afraid
by those who are selling treatments.
Stop allowing yourself to be influenced
by those who are selling you theories of
disease and drugs at the same time. And
I think that that um we have to become
much better healthy skeptics. We have to
think if someone's coming at you with a
prescription pad, you know that there's
something behind that. And whether it's
real or relevant to your life, you have
to sit back and think about things. And
um I would also say that that most of
the time if you're facing the sharp end
of a prescri prescription pad, you have
time to think about it. Most of the
time, not always, most of the time,
decisions around whether you start a
chronic drug for a chronic disease is
not an emergency situation. You have
time to do some research. Maybe watch a
few of your programs. You you you have
time to do a little bit of research. And
so, don't feel like um you know, the
sale ends tomorrow. You have to get on
board now. You have time to stop and
think.
>> Well, Alan Castles, it's such a pleasure
to have had you on.
>> Thank you for having me. Thank you all
for joining Alan Castles and me on this
episode of American Thought Leaders. I'm
your host Ya Kellik.